Method for treating cancer with c-kit antibodies

A method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an anti-C-KIT antibody or an antigen-binding portion thereof, wherein the antibody comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein

• (a) the VH region amino acid sequence comprises HCDR1 of GYTFTDYYMN (SEQ ID NO:
• 13), HCDR2 of MGRIYPGSGNTYYAQKFQG (SEQ ID NO:
• 14) and HCDR3 of GVYYYDY (SEQ ID NO:
• 15);
• and the VL region amino acid sequence comprises LCDR1 of RASQGIRTNLA (SEQ ID NO:
• 16), LCDR2 of AASSLQS (SEQ ID NO:
• 24) and LCDR3 of QQYNSYPRT (SEQ ID NO:
• 12);
• or
• (b) the VH region amino acid sequence comprises HCDR1 of GYTFTDYYMN (SEQ ID NO:
• 13), HCDR2 of MGRIYPGSGNTYYAQKFQG (SEQ ID NO:
• 14) and HCDR3 of GVYYYDY (SEQ ID NO:
• 15);
• and the VL region amino acid sequence comprises LCDR1 of RASQGIRTNLA (SEQ ID NO:
• 16), LCDR2 of AASSLQS (SEQ ID NO:
• 24) and LCDR3 of QQYANYPRT (SEQ ID NO:
• 25);
• and
• wherein the cancer is gastrointestinal stromal cancer (GIST), lung cancer, acute myeloid leukemia (AML) or a mast cell tumor.